Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (9): 1176-1181.doi: 10.3969/j.issn.1674-8115.2022.09.003

• Frontier review • Previous Articles    

Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy

HAN Yongqi1,2(), HAN Da1, XIA Qian1(), JI Dingkun1(), TAN Weihong1()   

  1. 1.Institute of Molecular Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200234, China
  • Received:2022-05-18 Accepted:2022-08-18 Online:2022-09-28 Published:2022-09-28
  • Contact: XIA Qian,JI Dingkun,TAN Weihong;;;
  • Supported by:
    Natural Science Foundation of Shanghai(22ZR1437800);Shanghai Sailing Program(20YF1424500)


Cancer is a worldwide medical issue that seriously threatens human health. Precision molecular medicine provides a new strategy for cancer theranostics. As excellent targeting recognition molecules and drug delivery platforms, aptamers and aptamer drug-conjugates (ApDCs) have provided a series of useful molecular tools for cancer precision therapy. In this paper, the properties and the selection techniques of aptamers, the construction of ApDCs and their applications to clinical tumor-targeting therapy are reviewed. Additionally, the challenges and perspective of ApDCs in precision molecular medicine for cancers are presented. This review may provide new horizons for molecular-targeted anti-tumor drugs in the therapy of clinical malignant tumors.

Key words: molecular medicine, aptamer, anti-cancer drug, targeted therapy

CLC Number: